6 million ($49 million) in a European IPO, earmarking its new cash to push a hepatitis B vaccine
into pivotal trials and hit the gas on an HIV
Abivax has registered about 2 million shares on the Euronext Paris exchange, setting aside another roughly 300,000 for its underwriters. The biotech will be placing shares through June 22, expecting to price them at a midpoint of €21.30 ($23.91) each. If Abivax's overallotment allocation comes through, the company could gross €57.7 million ($64.